share_log

Truist Securities Downgrades Fusion Pharmaceuticals to Hold, Raises Price Target to $21

Benzinga ·  Mar 19 11:56

Truist Securities analyst Nicole Germino downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold and raises the price target from $11 to $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment